This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (9)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Many Unanswered Questions

Anthony A. Gaspari, MD

Arch Dermatol. 1994;130(7):894-898.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

IN THIS volume of the ARCHIVES, Prussick et al¹ describe the unmasking of quiescent pemphigus vulgaris in a patient who received interleukin 2 immunotherapy for metastatic renal cell carcinoma.¹ Although interleukin 2 immunotherapy has been reported to cause mucocutaneous erosions,^2,3 these astute clinicians suspected another cause for the mucocutaneous erosions when the lesions persisted and progressed after the discontinuation of immunotherapy and were resistant to local therapy. These clinical features are in contrast to those of immunotherapy-induced mucocutaneous ulcerations that heal rapidly after a course of interleukin 2 immunotherapy. My previous histologic and direct immunofluorescence studies² (and unpublished data) of patients (n=10) who experienced interleukin 2 immunotherapy—induced mucocutaneous ulcerations did not reveal any specific patterns. This is in contrast to the study by Prussick and colleagues,¹ in which the direct immunofluorescence and histologic study of skin biopsy specimens confirmed the diagnosis of pemphigus vulgaris. This article, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?